Markus Zohner Arts Company is based in Lugano / Switzerland. The company produces Theatre Performances, Arts Projects, Podcast- and Radio Shows, offers trainings in Theatre, Creativity and Comunication, realizes Exhibitions and tours around the world. La Markus Zohner Arts Company ha sede a Lugano / Svizzera. La Compagnia produce spettacoli teatrali, progetti artistici, podcast, offre masterclasses per teatranti, realizza esposizioni, mostre fotografiche e multimediali e con le sue produzion ...
Travel Made Easy!
Life before, during and after the holocaust with Buchenwald survivor, Melvin Federbush. In hour 5 of this series, he reveals his harrowing experiences while in Nazi occupied Poland. Melvin Federbush was born in Deblin, Poland, July 1923. He attended Cheder and Yeshiva as well as high school. Within eight days of Hitler's invasion of Poland, his parents and nine year old twin sisters were killed during a bombing attack. Melvin was taken prisoner during the Nazi occupation and forced to live i ...
Broadcasting the latest developments in GU cancer
// LE CATALYSTE // "A Catalyst is a substance that causes or accelerates a chemical reaction." The purpose of the show is to bring together younger and older generations and people from various origins or styles showing how vast and rich is the culture and the history of the electronic music. "Le Catalyste" is weekly infused Podcast. At the begining, it was a French speaking radio show presented by Vince Kuzanagi on CKUM FM in Canada. While moving to France, it is temporarily turned into a p ...
Stefano Capasso is an international Dj and Producer. He starts his career working with Claudio Casalini and Claudio Donato. From "Riviera Romagnola" to Rome his set will become famous for the happy sound, the quality and the variety of his music (House, Soulful, Tech House and Disco Music often). Over the years divided the console with Dave Morales, Frankie Knuckles, Jamie Lewis, Martin Solveig, Carl Craig...Its main achievements: "Cadillac Car" (Purple Music) also remixed by Jamie Lewis, "C ...
son:DA belogs to that area of art characterised by linking of various technologies and media, as well as a new approach to the group work. son:DA is active in the fields of space installations, computer drawings, audio-video performances and different gallery project. Since 2000 son:DA has shown their work internationaly.Their solo exhibition were in Razstavnem salonu Rotovž Maribor, Kibla Maribor, Galeriji Meduza Koper, Likovnem salonu Celje, Galerij Kapelica Ljubljana, ARCO Madrid, Turner ...
Piet Ost, Chris Sweeney and Silke Gillessen discuss controversies around the management of oligometastatic prostate cancer.
Silke, Chris and Bertrand discuss bone protective therapy and bone targeted therapy.
Nick James and Chris Sweeney debate this issue. Tom and Silke try to keep things on track.
Laurence Albiges discusses renal cancer highlights from the year.
Matt discusses the year in review, including first line and adjuvant immune therapy studies, ADCs and FGFR targeting are also discussed.
A review of the year in prostate cancer with Chuck Ryan.
Christian Kollmannsberger gets into the Christmas spirit by discussing highlights of 2020.
Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups. Brian askes an interesting question at one point.
David McDermott and Brian Rini debate treatment options in front line renal cancer. It's hard to identify any winners from this podcast.
Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer.
Gretchen Vaughan, Kidney Cancer Association CEO, discusses the upcoming International Kidney Cancer Symposium meeting and KCA's grant program. Tom and Brian review some of the top abstracts.
'New Drugs vs New Biomarkers' Bill Kaelin (Nobel Laureate) vs Tom Powles (keen cyclist), extend their discussion from KCRS20 in the 2nd Uromigos Debate.
From podcasts to live recordings, 24 HOURS OF MUSIC over the week-end that the world can enjoy at its best moment.Alongside Urko, Romain Richard, Mike Storm, Errorbeauty,Dimitar Georgiev,Cardioactive,Markov,Human Koala,Octal Industries,Cyan341,c0ma,E M P T Y,Feryne,Jack Dover,Lenny Posso,Mike Griffin,Kerim Bey,SideChange,2OHM,Zadig,Fik, St…
Dr. Peter O'Donnell and Prof. Tom Powles debate front line treatment options in urothelial cancer.
A large randomised investigator-initiated Alliance study gives insight in to perioperative treatments for high risk prostate cancer.
This week, Le Catalyste is proud to resume and open its Fifth year with a true underground electronic Music Activist : ADJAndy Jaggers is a DJ, Producer, Label owner (Pyramid Transmissions Record), Events and club runner, radio show presenter. He was also records shop Owner at IQ records in the 90's !!As a DJ, he has played at many festivals and cl…
Nick gives us a quick summary of the STAMPEDE study and gives an overview of the latest data.
AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC.
Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC. A positive R3 trial in the ESMO plenary session.
The group go into the detail of chemo immune combinations and what to do next.
The group attempts to put the data into context with the other available combinations.
The group try to get to the bottom of whether these data has made any difference in treatment and future plans.
Andrea talks about her phase 2 trial which shows activity for Cabozantinib in urothelial cancer.
Old School electronica Set . made by Vince Kuzanagi for ECU event 08/2020https://mixlr.com/ecuInfinite thanks to Florence at @moicflo and EC Underground http://www.ecunderground.com/Tracklist:1 - Kenny Larkin - Tedra - Azimuth - Warp2 - Lawrel - Fireflies - Fireflies - inclusif 0043 - Iron Curtis - A1. 010103 - And The Temper - Office Recordings4 -…
Some thought it would never come - the final podcast of the World Tour from Boston.
Tom, Brian and Chris Sweeney discuss the challenges of development of biomarkers for immune therapy in bladder cancer.
Tom, David and Brian discuss biomarkers in renal cancer in the era of immune therapy.
Jan Oldenburg from Norway discusses treatment choices for stage 1 testis cancer, the dilemma of high dose therapy for relapse and long term toxicity of chemotherapy.
Axel Bex talks about small renal masses, robotic vs partial nephrectomy and surgery in metastatic disease.
The World Tour stays in Germany to discuss the first line renal cancer (clear cell and non-clear cell) and clinical trials with Oliver Grimm.
Jürgen discusses German research and surgery for bladder cancer. The podcast ends abruptly - which was not his fault!
Cristina Suarez discusses the success of clinical trials in Spain, and access to treatments.
Yoshi Tomita explains treatment pathways and research in GU cancer in Japan. Brian explains why he likes Japan so much.
Ian Davis discusses why ANZUP has been so successful, and the EnzaMet study. An uninvited guest arrives towards the end.
Ravi describes treatment pathways and research for Southeast Asia in GU cancer.
Juan Sade discusses research, treatment pathways in GU cancer, steak and red wine in Argentina.
The tour lands in sunny Brazil with a trip to a Japanese restaurant and a discussion about research and prostate cancer.
The Uromigos World Tour moves to Paris. Treatment for tumours that progress after first line immunetherapy is discussed. The role of Tivozanib is a focus for the dialogue.
Danny discusses Italian food and the past, present and future of the IMDC prognostic score.
Peter Black talks about his recent BCG refractory NMIBC ASCO presentation and its implications for the field.
Everything you wanted to know about FGFR inhibition but were afraid to ask.
Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations
Dr. Kala Sridhar, Professor Tom Powles and Dr. Brian Rini discuss the data presented at ASCO.
Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal, but it is difficult to interpret.
Joaquim Bellmunt explains a bit about why this trial was not successful and what it means for the field.
Thomas Hope is quizzed on the results of his study presented at ASCO20.
Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease.
Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds.
Mike Morris presents the findings in his prospective study.
Eric Jonasch discusses his ASCO presentation, which shows significant activity of HIF targeting in renal cancer patients with VHL syndrome.